Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy.
Int J Biochem Cell Biol. 2011 Jul;43(7):1010-20. doi: 10.1016/j.biocel.2010.05.001. Epub 2010 May 10.
Metabolomics, the study of metabolites and small intermediate molecules, may play a key role in further elucidation of breast cancer. This dynamic, simultaneous assessment of thousands of metabolites allows identification of the presence, concentration and fluxes of specific metabolites, and recognition of the critical metabolic pathways recruited in carcinogenesis. Studies of tumour cell and tissue allow focused analysis on the tumour, whilst studies of biofluids have the appeal of concurrent assessment of tumour and host. Elucidation of these metabolites and pathways may provide essential insights into both the intercellular environment and host/tumour interaction, allowing recognition of new biomarkers for diagnosis and prediction of outcome, new therapy targets and novel approaches for monitoring response and toxicity. Certainly, the field of metabolomics may evolve as a valuable, complementary clinical tool. In this review, current metabolomic data in breast cancer will be presented. The dominant metabolic pathways and metabolite disturbances associated with malignant transformation of breast cells will be outlined, leading to an overview of potential clinical implications for individuals with breast cancer.
代谢组学是研究代谢物和小分子中间产物的科学，可能在进一步阐明乳腺癌方面发挥关键作用。这种对数千种代谢物的动态、同步评估可以确定特定代谢物的存在、浓度和通量，并识别致癌过程中募集的关键代谢途径。对肿瘤细胞和组织的研究可以对肿瘤进行有针对性的分析，而对生物流体的研究则具有同时评估肿瘤和宿主的吸引力。阐明这些代谢物和途径可能为细胞间环境和宿主/肿瘤相互作用提供重要的见解，从而识别新的生物标志物用于诊断和预测结果、新的治疗靶点以及监测反应和毒性的新方法。当然，代谢组学领域可能会发展成为一种有价值的、互补的临床工具。在这篇综述中，将呈现乳腺癌的当前代谢组学数据。概述与乳腺细胞恶性转化相关的主要代谢途径和代谢物紊乱，从而概述乳腺癌个体的潜在临床意义。
